Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2016-11-08 Board/Management Inform…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVives rekrytering av Michele Tavecchio stärker forskningsorganisationen
Board/Management Information Classification · 1% confidence The document announces the recruitment of a senior researcher, Michele Tavecchio, to the company's research organization. It details his background, role, and quotes from management regarding the strategic fit. This type of announcement concerns changes in senior personnel or key scientific staff, which aligns best with the 'Board/Management Information' category, even though it is a research hire rather than a board member. The document is a press release format, dated November 8, 2016, and concludes with contact information for investors/media and a statement regarding disclosure obligations under EU market abuse regulation. Since the core subject is personnel change, MANG is the most appropriate fit over general regulatory filings (RNS).
2016-11-08 Swedish
NeuroVive’s recruitment of Michele Tavecchio strengthens its research organization
Board/Management Information Classification · 1% confidence The document announces the recruitment of a new senior scientist, Dr. Michele Tavecchio, detailing his role and background. This is an announcement concerning changes in senior personnel or management structure. This aligns directly with the definition for Board/Management Information (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a director's dealing (DIRS). Given the content, MANG is the most appropriate classification.
2016-11-08 English
NeuroVive rapporterar positiva prekliniska resultat i NASH
Regulatory Filings Classification · 1% confidence The document is a press release dated November 1, 2016, announcing positive preclinical results for a drug candidate (NVP018) in the NASH indication. It details scientific findings, management commentary, and updates on the company's business strategy. This type of announcement, focusing on specific research milestones or preliminary results outside of mandated periodic financial reports (like 10-K or IR), is typically classified as an Earnings Release (ER) if it relates to period results, or more generally as a Regulatory Filing (RNS) if it's a specific, non-financial operational update required for disclosure. Since it is a specific announcement of positive research data and strategy updates, and not a full financial report, a transcript, or a formal dividend/share change notice, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant operational news not covered by other specific codes. However, given the content is a direct announcement of operational/research progress, it is often categorized as an Earnings Release (ER) if it's the primary communication of recent operational performance/milestones, or sometimes as a Regulatory Filing (RNS). Since it is not a formal earnings report (ER) but a specific scientific update, RNS is the most appropriate general disclosure category here, as it is a required public disclosure ('skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning').
2016-11-01 Swedish
NeuroVive reports positive pre-clinical results in NASH
Regulatory Filings Classification · 1% confidence The document is a press release announcing positive pre-clinical results for a drug candidate (NVP018) in NASH treatment. It details scientific findings, management commentary, business strategy updates (out-licensing focus), and general company information. This type of announcement, focusing on specific scientific or operational updates outside of mandated periodic financial reporting (like 10-K or IR), is typically classified as an Earnings Release (ER) if it relates to period results, or more generally as a Regulatory Filing (RNS) if it's a broad operational update required for market transparency. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), and it is a material announcement to the market, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for important, non-standard announcements. Given the content is an operational/scientific update rather than a formal earnings summary, RNS is the most appropriate fit among the provided options, as it is a required disclosure under market regulations (implied by the final sentence referencing the EU Market Abuse Regulation).
2016-11-01 English
NeuroVive Pharmaceutical AB: Årsstämma 2017 och valberedning
AGM Information Classification · 1% confidence The document text is titled "Årsstämma 2017 och valberedning" (Annual General Meeting 2017 and Nomination Committee) and explicitly announces the date and time for the Annual General Meeting (AGM) on April 27, 2017. It also details the composition and mandate of the Nomination Committee preparing proposals for the AGM. This content directly relates to the proceedings and preparatory materials for the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4147 chars) is substantial enough to be the primary material, not just a brief announcement of a report (RPA/RNS).
2016-10-26 Swedish
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee
AGM Information Classification · 1% confidence The document explicitly announces the date and location of the 'Annual General Meeting 2017' and details the composition and tasks of the Nomination Committee related to that AGM. This content directly relates to the proceedings and preparatory materials for the Annual General Meeting. Although it contains information about the Nomination Committee (which might sometimes overlap with Governance or Management filings), the primary focus and title clearly indicate it is related to the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (4354 chars) is substantial enough that it is not merely a short announcement of a report (RPA/RNS), but the actual content related to the meeting.
2016-10-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.